<DOC>
	<DOCNO>NCT00711308</DOCNO>
	<brief_summary>The purpose study evaluate feasibility long-term treatment pulmonary embolism tinzaparin compare oral anticoagulant .</brief_summary>
	<brief_title>Tinzaparin Treatment Acute Pulmonary Embolism</brief_title>
	<detailed_description>The open-label prospective randomize clinical trial compare subcutaneous LMWH ( tinzaparin ) administer 6 month versus initial treatment use subcutaneous LMWH follow oral anticoagulant give 6 month patient acute venous thrombosis . To evaluate direct indirect cost treatment regimen rural population environment .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Symptomatic pulmonary embolism patient confirm : High probability ventilation/perfusion lung scan accord PIOPED criterion Spiral chest compute tomography , Pulmonary arteriography Aged 18 year , either sex The patient must provide sign informed consent Patients agree receive ambulatory anticoagulant treatment Massive pulmonary embolism Allergy heparin , component Tinzaparin acenocoumarol Previous thrombocytopenia induce heparin Thrombocytopenia &lt; 100000/mm3 History/signs/symptoms congenital bleeding disorder Life expectancy le 90 day Unfractioned heparin anticoagulation 36 hour prior enrollment Inability participate home tinzaparin program Clinical overt gastrointestinal blood loss due peptic ulcer , intestinal tumour , oesophagitis diverticulosis Hemoglobin low 7 g/dL Creatinin &gt; 3mg/dL Cerebralvascular accident Cerebral , medullary ophthalmological surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>pulmonary embolism</keyword>
	<keyword>low molecular weight heparin</keyword>
	<keyword>vitamin K antagonist</keyword>
	<keyword>Longterm</keyword>
</DOC>